New imaging technique aims to sharpen prostate cancer radiation

NCT ID NCT07393867

Recruiting now Knowledge-focused Sponsor: Martin T. King, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoiding healthy tissue. Participants will get standard treatments plus three imaging scans over six months. The goal is to make radiation more precise and reduce side effects in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA PET/CT imaging and androgen deprivation therapy (ADT) with or without bicalutamide
What this could lead to: If successful, this could lead to more precise radiation treatment for prostate cancer, potentially reducing side effects while maintaining effectiveness.
What could go wrong: This is a small, early-phase study with only 23 participants, so results may not apply to all patients. The imaging technique may not improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK PROSTATE CANCER INTERMEDIATE RISK PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
RECRUITING

Milford, Massachusetts, 01757, United States
Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital
RECRUITING

Weymouth, Massachusetts, 02190, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.